Clinical Trials
17 trialsNCT07059845 2026-06-04
FLORENZA
AbbVie
Phase 2 Recruiting
NCT05445778 2026-06-02
GLORIOSA
AbbVie
Phase 3 Active not recruiting
NCT06890338 2026-05-29
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
AbbVie
Phase 2 Recruiting
NCT06682988 2026-05-26
A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine
AbbVie
Phase 2 Recruiting
NCT04274426 2026-05-13
MIROVA
AGO Research GmbH
Phase 2 Active not recruiting
NCT06365853 2026-03-25
A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression
AbbVie
Phase 2 Recruiting
NCT07218809 2026-01-16
TREVI-OC-01
AstraZeneca
Phase 3 Recruiting
NCT05041257 2026-01-09
PICCOLO
AbbVie
Phase 2 Completed
NCT05483933 2025-12-23
Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers
Shattuck Labs, Inc.
Phase 1 Completed
NCT05456685 2025-10-28
Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer
AbbVie
Phase 2 Active not recruiting
NCT04209855 2025-08-27
MIRASOL
AbbVie
Phase 3 Completed
NCT06390995 2025-06-15
A Study of TAK-853 in Adult Participants With Folate Receptor Alpha-Positive Advanced Ovarian Cancer And Other Solid Tumors
Takeda
Phase 1/2 Active not recruiting
NCT04296890 2024-08-07
SORAYA
ImmunoGen, Inc.
Phase 3 Completed
NCT02606305 2024-06-14
Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer
ImmunoGen, Inc.
Phase 1/2 Completed
NCT05622890 2022-11-21
A Single-arm Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Epithelial Ovarian Cancer
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 3 Unknown
NCT01609556 2021-02-17
IMGN853-0401
ImmunoGen, Inc.
Phase 1 Completed
NCT02631876 2020-10-14
FORWARD I
ImmunoGen, Inc.
Phase 3 Completed